Aurinia Pharmaceuticals
AUPH
132 hedge funds and large institutions have $956M invested in Aurinia Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 47 increasing their positions, 31 reducing their positions, and 22 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 31
36% more call options, than puts
Call options by funds: $33.8M | Put options by funds: $24.9M
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
9% more capital invested
Capital invested by funds: $880M → $956M (+$76M)
6% more funds holding
Funds holding: 125 → 132 (+7)
1.76% less ownership
Funds ownership: 54.03% → 52.28% (-1.8%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$20.7M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$14.2M |
| 3 |
EP
Eversept Partners
New York
|
+$8.78M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$8.65M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$6.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$36.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$32.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.2M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$11.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.74M |
AUPH Hedge Fund Activity: Q2 2020 in Review
132 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2020, worth a combined $956M — up 8.6% from $880M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AUPH positions and 22 closed out — a net gain of 7 holders — while 47 added to existing stakes and 31 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $20.7M. The largest seller was Consonance Capital Management, cutting an estimated $36.6M.
- 132 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2020, up from 125 in Q1 2020.
- Funds reported $956M of Aurinia Pharmaceuticals stock for Q2 2020, up 8.6% quarter-over-quarter.
- 29 funds opened new Aurinia Pharmaceuticals positions in Q2 2020 and 22 closed out, a net change of +7 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2020 was Avidity Partners Management, an estimated $20.7M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2020 was Consonance Capital Management, an estimated $36.6M sold.
Based on aggregated 13F filings for Q2 2020.